E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Bleeding disorder, inherited deficiency in clotting factor VIII |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018938 |
E.1.2 | Term | Haemophilia A (Factor VIII) |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the clinical efficacy of N8-GP in bleeding prophylaxis (number of bleeding episodes during prophylaxis) in Chinese adolescent and adult patients with severe haemophilia A previously treated with other FVIII products |
|
E.2.2 | Secondary objectives of the trial |
In Chinese adolescent and adult patients with severe haemophilia A previously treated with other FVIII products, • To evaluate the clinical efficacy of N8-GP when used for treatment of bleeding episodes • To evaluate the immunogenicity of N8-GP • To evaluate the general safety of N8-GP • To evaluate the consumption of N8-GP • To evaluate the pharmacokinetic properties of N8-GP |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. 2. Male Chinese patient with severe congenital haemophilia A with a FVIII activity <1% according to medical records. 3. Aged ≥12 years at the time of signing informed consent. 4. History of at least 150 exposure days (EDs) to other FVIII products. 5. The patient and/or caregiver is capable of assessing a bleeding episode, keeping a diary, performing home treatment of bleeding episodes and otherwise following the trial procedures at the discretion of the investigator. |
|
E.4 | Principal exclusion criteria |
1. Known or suspected hypersensitivity to trial product or related products. 2. Previous participation in this trial. Participation is defined as signed informed consent. 3. Participation in any clinical trial of an approved or non-approved investigational medicinal product within 5 half-lives or 30 days from screening, whichever is longer. 4. Known history of FVIII inhibitors based on existing medical records, laboratory report reviews and patient and/or caregiver interviews. 5. Current FVIII inhibitors ≥0.6 BU. 6. Congenital or acquired coagulation disorder other than haemophilia According to medical records. 7. HIV positive, defined by medical records, with CD4+ count below or equal to 200/microL and a viral load >200 particles/μl or >400000 copies/mL within 6 months of the trial entry. If the data are not available in medical records within last 6 months, then the test must be performed at screening visit. 8. Previous significant thromboembolic events (e.g. myocardial infarction, cerebrovascular disease or deep venous thrombosis) as defined by available medical records. 9. Hepatic dysfunction defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 times the upper limit of normal combined with total bilirubin >1.5 times the upper limit of normal at screening, as defined by central laboratory. 10. Renal impairment defined as estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m^2 for serum creatinine measured at screening, as defined by central laboratory. 11. Platelet count <50×109/L at screening based on central laboratory values at screening. 12. Ongoing immune modulating or chemotherapeutic medication. 13. Any disorder, except for conditions associated with haemophilia A, which in the investigator`s opinion might jeopardise the patient`s safety or compliance with the protocol. 14. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Number of bleeding episodes |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From start of treatment until visit 7 |
|
E.5.2 | Secondary end point(s) |
Efficacy 1. Haemostatic effect of N8-GP when used for treatment of bleeding episodes, assessed on a four-point scale for haemostatic response (excellent, good, moderate and none) 2. Consumption of N8-GP for treatment of bleeding episodes 3. Consumption of N8-GP for prophylaxis 4. FVIII trough activity during prophylaxis
Safety 5. Incidence rate of confirmed FVIII inhibitors ≥0.6 BU 6. Number of adverse events (AEs) 7. Number of serious adverse events (SAEs)
PK 8. FVIII activity 30 min post-injection (C30min) 9. Incremental recovery (IR) 10. Area under the curve (AUC) 11. Terminal half-life (t½) 12. Clearance (CL) 13. FVIII trough activity 96 h post-injection (C96h) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1.-3., 5. From start of treatment until visit 7 4. From start of treatment (excluding the first exposure) until visit 7 6.-7. From start of treatment until end of trial 8.-9. Single-dose: 30 min ± 5 min post-injection at visit 2a, Steady-state: 30 min ± 5 min post-injection at visit 7 10.-12. Single-dose: 0−inf post-injection at visit 2a, Steady-state: 0−96 h post-injection at visit 7 13. Single-dose: 96 h ± 8 h post-injection at visit 2a, Steady-state: 96 h ± 8 h post-injection at visit 7 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |